Abstract: A molded fiber part former includes a first forming mold defining a first mold area and at least one fluid inlet. The molded fiber part former also includes a wall substantially surrounding the first mold area. The molded fiber part former includes a fluid channel disposed adjacent to and surrounding the wall, wherein the channel is fluidically connected to the at least one fluid inlet and defines a fluid channel outlet.

Abstract: A molded fiber part former includes a first forming mold defining a first mold area and at least one fluid inlet. The molded fiber part former also includes a wall substantially surrounding the first mold area. The molded fiber part former includes a fluid channel disposed adjacent to and surrounding the wall, wherein the channel is fluidically connected to the at least one fluid inlet and defines a fluid channel outlet.

Abstract: A molded fiber part former includes a first forming mold defining a first mold area and at least one fluid inlet. The molded fiber part former also includes a wall substantially surrounding the first mold area. The molded fiber part former includes a fluid channel disposed adjacent to and surrounding the wall, wherein the channel is fluidically connected to the at least one fluid inlet and defines a fluid channel outlet.

Abstract: The present invention refers to a new monoclonal antibody or fragment thereof, called 14F5F6, which specifically recognizes herpes simplex virus (HSV), in its two types, herpes simplex virus type 1 and herpes simplex virus type 2 (HSV-1 and HSV-2). Preferably, the antibody of the invention is useful for the development of methods for the diagnosis of herpes simplex virus infection, as well as for the production of pharmaceutical compositions intended for the treatment, protection and/or prophylaxis of infection specifically caused by HSV-1 and HSV-2.

Abstract: A molded fiber part production line includes a forming station, a part transfer system, a press station, and a removal system. The forming station includes a slurry tank, a forming mold, and a mold actuation system. The part transfer system includes a part transfer feature and a conveyance mechanism. The press station includes a core mold, a cavity mold compatible with the core mold, and a press actuation system. The removal system includes a removal feature defining a plurality of part vacuum channels and a plurality of trim vacuum channels. The removal system also includes a conveyance mechanism for moving the removal feature from a position in engagement with at least one of the core mold and the cavity mold to another position.

Abstract: A molded fiber part production line includes a forming station, a part transfer system, a press station, and a removal system. The forming station includes a slurry tank, a forming mold, and a mold actuation system. The part transfer system includes a part transfer feature and a conveyance mechanism. The press station includes a core mold, a cavity mold compatible with the core mold, and a press actuation system. The removal system includes a removal feature defining a plurality of part vacuum channels and a plurality of trim vacuum channels. The removal system also includes a conveyance mechanism for moving the removal feature from a position in engagement with at least one of the core mold and the cavity mold to another position.

Abstract: The present invention refers to a new monoclonal antibody or fragment thereof, called 11B2C7, which specifically recognizes herpes simplex virus (HSV), in its two types, herpes simplex virus type 1 and herpes simplex virus type 2 (HSV-1 and HSV-2). Preferably, the antibody of the invention is useful for the development of methods for the diagnosis of herpes simplex virus infection, as well as for the production of pharmaceutical compositions intended for the treatment, protection and/or prophylaxis of infection specifically caused by HSV-1 and HSV-2.

Abstract: A charger includes first and second rail circuits and a controller. Each of the first and second rail circuits provide power when activated. The controller activates the first rail circuit without activating the second rail circuit in accordance with a determination that a power greater than a first power and less than a second power is to be provided. The controller activates the first and second rail circuits in accordance with a determination that a power greater than the second power is to be provided. A power difference between the second power and the first power is greater than the first power.

Abstract: It is provided a method, device and system to facilitate the design or and architecture of a computer project and its subsequent automatic implementation, based on a hand-written/drawn draft (e.g. on paper). This draft directly becomes the tool that will be used, automatically, as the basis for the final computer project implementation.

Abstract: A molded fiber part former includes a first forming mold defining a first mold area and at least one fluid inlet. The molded fiber part former also includes a wall substantially surrounding the first mold area. The molded fiber part former includes a fluid channel disposed adjacent to and surrounding the wall, wherein the channel is fluidically connected to the at least one fluid inlet and defines a fluid channel outlet.

Abstract: A molded fiber part former includes a first forming mold defining a first mold area and at least one fluid inlet. The molded fiber part former also includes a wall substantially surrounding the first mold area. The molded fiber part former includes a fluid channel disposed adjacent to and surrounding the wall, wherein the channel is fluidically connected to the at least one fluid inlet and defines a fluid channel outlet.

Abstract: The invention relates to an immunogenic formulation containing one or more modified recombinant strains of Bacillus Calmette-Guerin (BCG), in a concentration between 104?109 bacteria, where each BCG strain expresses at least one protein or immunogenic fragment of SARS-CoV-2, in a pharmaceutically acceptable saline buffer, where this formulation serves to prepare vaccines to prevent, treat or attenuate SARS-CoV-2 infections.

Abstract: The system comprises a plurality of cameras, wherein a first camera is configured to acquire a first captured image and a second camera is configured to acquire a second captured image, the first captured image and the second captured image being at least partially overlapped; at least one controller configured to receive and combine at least the first captured image and the second captured image for providing the composite image; and the system is configured to define a first region of interest within the first captured image and a second region of interest within the second captured image; and to detect the at least one of a brightness and a color of at least the first and second region of interest to adjust the at least one of the brightness and the color of at least the first and second captured image before being combined.

Abstract: Lightweight and man-portable lights may be used to provide a rapid and deployable aircraft landing zone illumination solution. The lights may produce a combination of visible and infrared (IR) light. The lights may be mounted using stakes or concrete anchors, or they can be left unmounted on the ground for easy and rapid deployment. The light may include five types of visible light-emitting diodes (LEDs)—white (W), yellow (Y), green (G), red (R), and blue (B)—and infrared (IR) LEDs. The LEDs (visible and IR) can be controllable between different intensities. The light may include built-in wireless communication capabilities. A number of lights may be positioned and then operated together for landing zone and emergency lighting solutions.

Abstract: A predictive maintenance system for a conveyor belt system may include a predictive maintenance device, which may be in communication with a central station. The device may communicate with the central station via a wired or wireless communication system. The conveyor belt system includes a belt for transporting product or material, which exert force on the belt which may eventually lead to wear or catastrophic failure of the belt. A device driver in the device may receive data from sensors and use the data to provide predictive maintenance models and detect faults.

Abstract: The invention relates to an immunogenic formulation containing the bacillus Calmette-Guerin (BCG) strain in a concentration between 104-109 bacteria, expressing at least one protein or immunogenic fragment of Andesvirus (ANDV), in a pharmaceutically acceptable saline buffer solution, which serves to prepare a vaccine useful for preventing, treating or attenuating ANDV infections. ANDV belongs to the Hantavirus family and is a highly virulent human pathogen, which annually affects dozens of people in Chile generating in some infected a Hantavirus Cardiopulmonary Syndrome (HCPS).

Abstract: A molded fiber part former includes a first forming mold defining a first mold area and at least one fluid inlet. The molded fiber part former also includes a wall substantially surrounding the first mold area. The molded fiber part former includes a fluid channel disposed adjacent to and surrounding the wall, wherein the channel is fluidically connected to the at least one fluid inlet and defines a fluid channel outlet.

Abstract: The invention relates to the novel use of an immunogenic formulation containing Bacillus Calmette-Guerin (BCG) in a concentration between 104-109 bacteria, which recombinantly expresses at least one protein or immunogenic fragment of the human Respiratory Syncytial Virus (hRSV, human orthopneumovirus), stabilized in a pharmaceutically acceptable saline buffer solution to prevent, treat, or attenuate bRSV infections in cattle.

Abstract: The invention relates to the novel use of an immunogenic formulation containing the bacillus Calmette-Guérin (BCG) strain at a concentration between 104-109 bacteria, expressing at least one protein or immunogenic fragment of respiratory syncytial virus (RSV, Human orthopneumovirus), in a pharmaceutically acceptable saline buffer solution because it serves to prepare a vaccine useful to prevent, treat, or attenuate human metapneumovirus (hMPV) infections.

Abstract: Composition with antiviral activity comprising water-soluble extracts of Durvillaea antarctica substantially free of alginates and a carrier or vehicle, and the method of obtaining it. Where this composition serves to prepare an antiviral drug of topical application, to prevent or treat skin or oral lesions caused by herpes viruses of the subfamily Alphahehrpesvirinae, such as herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2) and varicella zoster virus (VZV), resistant or not to acyclovir (ACV).